Maze Therapeutics IPO opens trading modestly higher

Stocks and Investing Stocks and Investing

Sat, February 1, 2025

[ Yesterday Evening ] - Mint

Budget 2025 share market impact Highlights: Sense .. t amid high volatility; FMCG, realty stocks rally

[ Yesterday Afternoon ] - cnbctv18

Budget 2025: Positive or Negative? How have insurance stocks fared post the FM speech?

[ Yesterday Afternoon ] - MSN

How I'd unlock more passive income from the iShares S&P 500 ETF (IVV)

[ Yesterday Afternoon ] - MSN

5 Warren Buffett Stocks for Generating Passive Di .. e Even If There's a Stock Market Sell-Off in 2025

[ Yesterday Afternoon ] - MSN

These were the worst performing ASX 200 shares in January 2025

[ Yesterday Afternoon ] - MSN

Invested $100 in eBay Stock Almost 30 Years Ago? It Would Be Over $9K Today

[ Yesterday Afternoon ] - MSN

Franklin Resources, Inc. (NYSE:BEN) Q1 2025 Earnings Call Transcript

[ Yesterday Afternoon ] - MSN

The Week's Investing News Roundup: Cathie Wood Picks, Stock-Split Contenders, and More

[ Yesterday Morning ] - MSN

7 Must-Have Accounts to Achieve Financial Independence

[ Yesterday Morning ] - MSN

Why W.W. Grainger (GWW) Shares Are Getting Obliterated Today

[ Yesterday Morning ] - MSN

Want $3,000 in Annual Dividends? Invest $17,000 in Each of These 3 High-Yielding Stocks

[ Yesterday Morning ] - MSN

Should You Buy W.P. Carey While It's Below $60?

Fri, January 31, 2025

[ Last Friday ] - MSN

Invest $50,000 in This Stock and Get $2,950 Back Per Year in Dividends

[ Last Friday ] - MSN

Meet the Canadian Stock That Continues to Crush the Market

[ Last Friday ] - MSN

Shopify stock soars to 52-week high of $120.81

[ Last Friday ] - MSN

3 Monthly Dividend Stocks to Buy and Hold Forever

[ Last Friday ] - MSN

How much money a $1,000 investment in Apple 10 years ago would be worth today

[ Last Friday ] - MSN

Maze Therapeutics IPO opens trading modestly higher

[ Last Friday ] - Kiplinger

Stock Market Today: Trump Tariff Worries Pressure Stocks

[ Last Friday ] - MSN

Is It Worth Investing in AST SpaceMobile (ASTS) Based on Wall Street's Bullish Views?

[ Last Friday ] - Investopedia

Top Stock Movers Now: Apple, AbbVie, Deckers Outdoor, and More

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of MYSZ at $1 .. 95, after crossing above the $1.949 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of RGBPP at $ .. 09, after crossing above the $0.072 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of NMFC at $1 .. 5, after crossing above the $11.656 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of NBY at $0. .. 73, after crossing above the $0.662 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of HLGN at $1 .. 06, after crossing above the $1.057 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of PDFS at $2 .. 3, after crossing above the $27.628 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of PCLB at $2 .. 96, after crossing above the $29.15 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of LENZ at $2 .. 9, after crossing above the $26.843 Trigger Price

[ Last Friday ] - WOPRAI

Short squeeze is starting in shares of CSPI at $1 .. 4, after crossing above the $18.842 Trigger Price

Maze Therapeutics IPO opens trading modestly higher

^{Published on 2025-01-31 18:21:09 - MSN}

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced 8,750,000 shares of its common stock at a public offering price of $16.

The article from MSN Money discusses the initial public offering (IPO) of Maze Therapeutics, a biotechnology company focused on developing treatments for genetically defined diseases. On its first day of trading, Maze Therapeutics' stock opened modestly higher, reflecting cautious optimism from investors. The company aims to leverage its expertise in genetic medicine to address unmet medical needs, particularly in rare diseases. The IPO pricing and initial trading performance suggest a balanced market reception, with investors weighing the potential of Maze's innovative approach against the inherent risks of biotech investments. The article also touches on the broader context of the biotech sector, where IPOs are closely watched for indications of market sentiment towards high-risk, high-reward ventures.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/maze-therapeutics-ipo-opens-trading-modestly-higher/ar-AA1yckOq ]

Contributing Sources